Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Subjects With Amyotrophic Lateral Sclerosis (ALS)
NCT04579666 is registered in ClinicalTrials.gov with Apellis Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Subjects With Amyotrophic Lateral Sclerosis (ALS)
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- September 30, 2020
- Completion date
- July 13, 2023
- Enrollment
- 249 (actual)
- Sites
- 60
Conditions
As the registry lists them; a condition with its own page is linked.